Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01951339

Enrollment

Registered

2013-09-26

Start date

2013-10-31

Completion date

2018-06-30

Last updated

2023-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Disease, Type 2 Diabetes

Keywords

diabetes, type 2 diabetes, exercise, echo, heart, sitagliptin, glimepiride, cardiovascular

Brief summary

The goal of this study is to examine whether sitagliptin, an agent which enhances the action of hormones that control the release of insulin and is already in clinical use for type 2 diabetes, might also improve functional exercise capacity. Specific aims: 1\. To test whether sitagliptin will improve functional exercise capacity in persons with type 2 diabetes compared to glimepiride. 1a. The primary outcome will be peak oxygen consumption (VO2peak) and oxygen uptake kinetics (VO2 kinetics). 1b. Secondary outcomes include cardiac function, endothelial function and tissue oxygen saturation (STO2) as well as health-related quality of life. 2\. To evaluate the impact of sitagliptin on muscle mitochondrial function 2a. The primary outcome to address this aim will be 31P measurements (phosphocreatine, free inorganic phosphate, adenosine triphosphate peaks, adenosine diphosphate and pH) Impact: Novel approaches are needed to decrease excess cardiovascular morbidity and mortality in diabetes. Diabetes impairs cardiovascular fitness and thereby mortality. A demonstration that sitagliptin improves cardiovascular fitness, (and possibly mitochondrial function) will provide important new data pertinent to the management of diabetes and pre-diabetes.

Detailed description

Subjects will come for a total of nine testing visits during which evaluations will take place. Visits are structured as follows: 1. After subjects review the study and give consent for study participation, a history and physical exam will be performed. Ankle brachial index, autonomic nervous system function tests, the Low-level Physical Activity Recall questionnaire and vital signs will be performed. 2. Blood drawn for measurement of hemoglobin A1C, fasting glucose, fasting insulin, free fatty acids and microalbuminuria, c-reactive protein, interleukin 6, adiponectin, and creatinine and glycerol. Additional screening labs include complete blood count (CBC), follicle-stimulating hormone, urine protein and a lipid panel to assess whether women are pre- or post-menopausal (FSH), and overall health (CBC, lipids and urine protein). A dietary survey will be administered for food preferences for the three day study diet administered prior to visits 3-5 and 7-9. Dual-energy xray absorptiometry (DEXA) and body composition tests will be done to ensure that groups are weight similar (using fat-free mass). A pulmonary function test, resting electrocardiogram (EKG) and familiarization bicycle test will be performed. 3. Subjects will receive a three day study diet prior to visit 3. A resting and exercise EKG will be performed on the day of the visit. A graded exercise test will be done to determine the VO2peak. Patients will have measures of cardiac function and endothelial function on visit 3 by plethysmography and cardiac echo. Vital signs will be taken at rest. 4. Subjects will receive a three day study diet prior to visit 4. Calf muscle magnetic resonance spectroscopy (MRS) will be performed on a 3.0 T whole-body MRI scanner. 5. During visit 5, arterial stiffness/endothelial function will be non-invasively measured by the Sphygmocor system. Subjects will also have three constant-load tests to measure VO2 kinetics where oxygen saturation (StO2) will be measured during exercise. A resting and exercise EKG and vital signs will be performed during the visit. Subjects will be randomized to taking sitagliptin plus placebo or glimepiride plus placebo and all must be taking metformin (1-2 grams /d) for 3 months. Sitagliptin and its placebo will be administered 100 mg/d. Glimepiride and its placebo will be administered 2 mg/day. During the treatment phase subjects will be given a log to keep track of their blood glucose each day. 6. Visit 6 will consist of a physical exam with a clinician as well as a blood draw and check of vital signs during sitagliptin or glimepiride treatment. 7. After 3 months of sitagliptin or glimepiride administration, Visit 3 will be repeated. Additional testing to be performed during visit 7 will include a physical exam performed by a study physician, blood work for covariate lab tests listed in Visit 2 and the Low-level Physical Activity Recall(LoPAR) questionnaire. 8. During visit 8, visit 4 procedures will be repeated. 9. During visit 9, the testing performed during visit 5 will be repeated.

Interventions

DRUGSitagliptin

100 mg sitagliptin

DRUGGlimepiride

Active Comparator 2mg glimepiride

DRUGPlacebo

2 mg placebo once daily

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

22 Years to 70 Years

Healthy volunteers

Inclusion criteria

1. Female subjects may be pre, peri or post-menopausal. 2. People who do not participate in a regular exercise program (\> one bout of exercise per week). 3. Presence of type 2 diabetes will be documented by chart review that will confirm the diagnosis as well as the presence of treatment for diabetes. 4. Persons with type 2 diabetes will be accepted for study only if they have total glycosylated hemoglobin levels (HbA1C) between 7 and 9.5% (adequate control) on therapy. 5. Persons who are taking metformin 500-2000 mg/day only to control their T2D, but are not taking any other diabetes medication in addition to or instead of metformin. 6. Persons not taking medication to control diabetes.

Exclusion criteria

1. Females of childbearing potential who are pregnant, planning to become pregnant or breastfeeding. 2. Persons will be excluded if they have evidence of ischemic heart disease by history or abnormal resting or exercise electrocardiogram (EKG) (\> 1 mm ST segment depression), regional wall motion abnormalities, left ventricular systolic dysfunction or significant valvular disease. 3. Persons with angina or any other cardiac or pulmonary symptoms potentially limiting exercise performance. 4. Presence of systolic blood pressure \>190 at rest or \>250 with exercise or diastolic pressure \>95 at rest or \>115 with exercise. 5. Subjects who have peripheral arterial disease. 6. Subjects with proteinuria (urine protein \>200 mg/dl) or a creatinine \> 2 mg/dl, suggestive of renal disease. 7. Persons with liver function impairment defined as elevated liver function tests three times the upper limit. 8. Persons with a history of pancreatitis. 9. Subjects more than 140% of ideal body weight. 10. Patients on insulin therapy will not be included. 11. Current smokers will not be accepted for study since smoking can impair cardiovascular exercise performance but people who have quit smoking for at least 1year will be accepted for study. 12. Persons with autonomic dysfunction (\>20 mm fall in upright blood pressure without a change in heart rate) will be excluded. 13. Diabetic persons with clinically evident distal symmetrical neuropathy will be excluded from further study, because of possible effects on exercise performance, by evaluation of symptoms (numbness, paresthesia) and signs (elicited by vibration, pinprick, light touch, ankle jerks). 14. Persons with diabetic ketoacidosis. 15. Persons with a serious hypersensitivity to sitagliptin, sulfonylureas or sulfonamides. 16. Inability to walk or ride a bike unassisted for a continuous 5 minutes. 17. Subjects will be excluded if they have any implanted metal in their body. 18. Subjects currently being treated with Digoxin.

Design outcomes

Primary

Measure	Time frame	Description
Changes From Baseline in 31P Measurement: pH	Pre-intervention (Baseline) and post-intervention (3 months)	Potential change in muscle mitochondrial function will be assessed after three months of study medication treatment
Changes From Baseline in 31P Measurement: Adenosine Triphosphate (ATP) Peaks	Pre-intervention (Baseline) and post-intervention (3 months)	Potential change in muscle mitochondrial function will be assessed after three months of study medication treatment
Changes From Baseline in 31P Measurement: Adenosine Diphosphate (ADP) Time Constant	Pre-intervention (Baseline) and post-intervention (3 months)	Potential change in muscle mitochondrial function will be assessed after three months of study medication treatment
Peak Oxygen Consumption (VO2peak).	Pre-intervention (Baseline) and post-intervention (3 months)	Subjects' peak oxygen consumption will be tested on a stationary bike before and after 3 months of study medication.
Changes From Baseline in 31P Measurement: Phosphocreatine Time Constant	Pre-intervention (Baseline) and post-intervention (3 months)	Potential change in muscle mitochondrial function will be assessed after three months of study medication treatment
Change in Oxygen Uptake Kinetics (VO2 Kinetics)	Pre-intervention (Baseline) and post-intervention (3 months)	Oxygen uptake kinetics will be tested on a stationary bike before and after 3 months of study medication. VO2 kinetics is reported as the time constant associated with the change in oxygen update from rest to steady state.
Changes From Baseline in 31P Measurement: Free Pi Time Constant	Pre-intervention (Baseline) and post-intervention (3 months)	Potential change in muscle mitochondrial function will be assessed after three months of study medication treatment. Data are represented as the change in Pi through the scan.

Secondary

Measure	Time frame	Description
Change in (Non-invasively Measured) Deoxygenated Hemoglobin Concentration in the Vastus Lateralis During Exercise	Pre-intervention (Baseline) and post-intervention (3 months)	Deoxygenated hemoglobin concentration will be measured using near-infrared spectroscopy during sub-maximal exercise before and after 3 months of study drug administration.
Changes From Baseline in Echocardiographic Measures (Stroke Volume)	Pre-intervention (Baseline) and post-intervention (3 months)	Potential change in cardiac function will be assessed by echocardiography before and after 3 months of study medication

Countries

United States

Participant flow

Pre-assignment details

Patients underwent screening, as well as baseline data collection prior to randomization to group. Several patients withdrew from the study prior to randomization.

Participants by arm

Arm	Count
Sitagliptin Plus Placebo 100 mg sitagliptin plus 2 mg placebo once daily for three months Sitagliptin: 100 mg sitagliptin Placebo: 2 mg placebo once daily	13
Glimepiride Plus Placebo 2 mg glimepiride plus 100 mg placebo once daily for three months Glimepiride: Active Comparator 2mg glimepiride Placebo: 100 mg placebo once daily for three months	14
Total	27

Baseline characteristics

Characteristic	Glimepiride Plus Placebo	Total	Sitagliptin Plus Placebo
Age, Categorical <=18 years	0 Participants	0 Participants	0 Participants
Age, Categorical >=65 years	3 Participants	5 Participants	2 Participants
Age, Categorical Between 18 and 65 years	11 Participants	22 Participants	11 Participants
Age, Continuous	57 years STANDARD_DEVIATION 3	57 years STANDARD_DEVIATION 8	59 years STANDARD_DEVIATION 2
Race (NIH/OMB) American Indian or Alaska Native	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Asian	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Black or African American	1 Participants	5 Participants	4 Participants
Race (NIH/OMB) More than one race	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants	1 Participants	1 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) White	13 Participants	21 Participants	8 Participants
Region of Enrollment United States	14 participants	27 participants	13 participants
Sex: Female, Male Female	6 Participants	13 Participants	7 Participants
Sex: Female, Male Male	8 Participants	14 Participants	6 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk
deaths Total, all-cause mortality	0 / 15	0 / 15
other Total, other adverse events	5 / 15	3 / 15
serious Total, serious adverse events	0 / 15	0 / 15

Outcome results

Primary

Change in Oxygen Uptake Kinetics (VO2 Kinetics)

Oxygen uptake kinetics will be tested on a stationary bike before and after 3 months of study medication. VO2 kinetics is reported as the time constant associated with the change in oxygen update from rest to steady state.